SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF ABEMACICLIB IN THE TREATMENT OF HR+ HER2− ADVANCED OR METASTATIC BREAST CANCER . YHCĐ 2026, 67 (10). https://doi.org/10.52163/yhc.v67i10.6967.